Profile pacjentów z bólem niereceptorowym, u których zastosowano pregabalinę Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lis 30, 2025
Słowa kluczowe:
pregabalina, ból niereceptorowy, lęk uogólniony, padaczka
##plugins.themes.bootstrap3.article.main##
Abstrakt
Artykuł omawia zastosowanie pregabaliny w leczeniu bólu niereceptorowego, szczególnie neuropatycznego i nocyplastycznego, a także jej rolę w terapii lęku uogólnionego i padaczki. Przedstawiono mechanizm działania leku oraz jego skuteczność kliniczną na przykładzie dwóch przypadków pacjentek z różnymi profilami bólu i współchorobowościami. Pregabalina, dzięki dobremu profilowi bezpieczeństwa i udokumentowanej skuteczności, stanowi ważne narzędzie terapeutyczne w leczeniu złożonych zespołów bólowych, zwłaszcza u pacjentów wielochorobowych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Białecka , M. (2025). Profile pacjentów z bólem niereceptorowym, u których zastosowano pregabalinę . Medycyna Faktów , 18(3(68), 466-472. https://doi.org/10.24292/01.MF.0325.19
Numer
Dział
Artykuły
Copyright by Medical Education. All rights reserved.
Bibliografia
1. Stahl SM, Porreca F, Taylor CP et al. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013; 34: 332-9.
2. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73(2): 137-50.
3. Rometsch C, Martin A, Junne F et al. Chronic pain in European adult populations: a systematic review of prevalence and associated clinical features. Pain. 2025; 166(4): 719-31. http://doi.org/10.1097/j.pain.0000000000003406.
4. Nijs J, Kosek E, Chiarotto A et al. Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium’s international and multidisciplinary consensus recommendations. Lancet Rheumatol. 2024; 6(3): e178-88. http://doi.org/10.1016/S2665-9913(23)00324-7.
5. Soliman N, Moisset X, Ferraro MC et al.; NeuPSIG Review Update Study Group. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025; 24(5): 413-28. http://doi.org/10.1016/S1474-4422(25)00068-7.
6. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and metaanalysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
7. Davari M, Amani B, Amani B et al. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: A systematic review and meta-analysis. Korean J Pain. 2020; 33(1): 3-12. http://doi.org/10.3344/kjp.2020.33.1.3.
8. Allam AK, Sharma H, Larkin MB et al. Trigeminal Neuralgia: Diagnosis and Treatment. Neurol Clin. 2023; 41(1): 107-21. http://doi.org/10.1016/j.ncl.2022.09.001.
9. Fagan HA, Baldwin DS. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. 2023; 23(6): 535-48.
10. Stein DJ, Baldwin DS, Baldinetti F et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008; 18(6): 422-30.
11. Rejdak K, Mazurkiewicz-Bełdzińska M, Błaszczyk B et al. Diagnostyka i leczenie padaczki – rekomendacje Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny 2022; 18(4): 201-19.
12. Bockbrader HN, Wesche D, Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10): 661-9.
13. Raouf M, Bettinger J, Wegrzyn EE et al. Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease. Kidney Dis (Basel). 2020; 6(3): 157-67. http://doi.org/10.1159/000504299.
14. Terminology. International Association for the Study of Pain (IASP).
15. Bułdyś K, Górnicki T, Kałka D et al. What Do We Know about Nociplastic Pain? Healthcare (Basel). 2023; 11(12): 1794. http://doi.org/10.3390/healthcare11121794.
16. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011; 123(5): 134-42.
17. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. Standards of Care in Diabetes. The position of Diabetes Poland – 2024. Current Topics in Diabetes. 2023; 3(3-4): 1-348. https://doi.org/10.5114/ctd/183052.
18. Tong C, Zhengyao Z, Mei L et al. Pregabalin and Gabapentin in Patients with Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis. Pain Ther. 2021; 10(2): 1497-509.
19. Winkelman JW, Berkowski JA, DelRosso LM et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025; 21(1): 137-52.
20. Atış G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatol Ther. 2017; 30(2). http://doi.org/10.1111/dth.12459.
21. Guilleminault L, Grassin-Delyle S, Mazzone SB. Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough. Drugs. 2024; 84(7): 763-77. http://doi.org/10.1007/s40265-024-02047-y.
22. Drug Scheduling & Classifications (List of Schedule I-V Controlled rugs).
2. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73(2): 137-50.
3. Rometsch C, Martin A, Junne F et al. Chronic pain in European adult populations: a systematic review of prevalence and associated clinical features. Pain. 2025; 166(4): 719-31. http://doi.org/10.1097/j.pain.0000000000003406.
4. Nijs J, Kosek E, Chiarotto A et al. Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium’s international and multidisciplinary consensus recommendations. Lancet Rheumatol. 2024; 6(3): e178-88. http://doi.org/10.1016/S2665-9913(23)00324-7.
5. Soliman N, Moisset X, Ferraro MC et al.; NeuPSIG Review Update Study Group. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025; 24(5): 413-28. http://doi.org/10.1016/S1474-4422(25)00068-7.
6. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and metaanalysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
7. Davari M, Amani B, Amani B et al. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: A systematic review and meta-analysis. Korean J Pain. 2020; 33(1): 3-12. http://doi.org/10.3344/kjp.2020.33.1.3.
8. Allam AK, Sharma H, Larkin MB et al. Trigeminal Neuralgia: Diagnosis and Treatment. Neurol Clin. 2023; 41(1): 107-21. http://doi.org/10.1016/j.ncl.2022.09.001.
9. Fagan HA, Baldwin DS. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. 2023; 23(6): 535-48.
10. Stein DJ, Baldwin DS, Baldinetti F et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008; 18(6): 422-30.
11. Rejdak K, Mazurkiewicz-Bełdzińska M, Błaszczyk B et al. Diagnostyka i leczenie padaczki – rekomendacje Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny 2022; 18(4): 201-19.
12. Bockbrader HN, Wesche D, Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10): 661-9.
13. Raouf M, Bettinger J, Wegrzyn EE et al. Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease. Kidney Dis (Basel). 2020; 6(3): 157-67. http://doi.org/10.1159/000504299.
14. Terminology. International Association for the Study of Pain (IASP).
15. Bułdyś K, Górnicki T, Kałka D et al. What Do We Know about Nociplastic Pain? Healthcare (Basel). 2023; 11(12): 1794. http://doi.org/10.3390/healthcare11121794.
16. Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011; 123(5): 134-42.
17. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. Standards of Care in Diabetes. The position of Diabetes Poland – 2024. Current Topics in Diabetes. 2023; 3(3-4): 1-348. https://doi.org/10.5114/ctd/183052.
18. Tong C, Zhengyao Z, Mei L et al. Pregabalin and Gabapentin in Patients with Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis. Pain Ther. 2021; 10(2): 1497-509.
19. Winkelman JW, Berkowski JA, DelRosso LM et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2025; 21(1): 137-52.
20. Atış G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatol Ther. 2017; 30(2). http://doi.org/10.1111/dth.12459.
21. Guilleminault L, Grassin-Delyle S, Mazzone SB. Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough. Drugs. 2024; 84(7): 763-77. http://doi.org/10.1007/s40265-024-02047-y.
22. Drug Scheduling & Classifications (List of Schedule I-V Controlled rugs).